Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 01 2019
24 01 2019
Historique:
received:
26
06
2018
accepted:
23
11
2018
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
28
7
2020
Statut:
epublish
Résumé
Soluble urokinase plasminogen activation receptor (suPAR) is risk factor for kidney disease and biomarker for cardiovascular outcomes but long term longitudinal analyses in a large European cohort have not been perfomed. To hus, we studied suPAR in participants of the Ludwigshafen Risk and Cardiovascular Health study over a very long follow-up time of nearly 10 years. We estimated overall risk of all-cause and cardiovascular death by Cox proportional hazards regression according to quartiles of suPAR, including age, sex, use of lipid-lowering drugs, body mass index, diabetes mellitus, hypertension, smoking, lipids, as well as glomerular filtration rate (eGFR), NT-proBNP, interleukin-6 and high-sensitive CRP as covariates. A total of 2940 participants (age 62.7 ± 10.5years) having a median eGFR of 83.8 mL/min/1.73 m
Identifiants
pubmed: 30679668
doi: 10.1038/s41598-018-36960-6
pii: 10.1038/s41598-018-36960-6
pmc: PMC6346054
doi:
Substances chimiques
Biomarkers
0
Receptors, Urokinase Plasminogen Activator
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
475Références
Pharmacogenomics. 2001 Feb;2(1 Suppl 1):S1-73
pubmed: 11258203
Blood Coagul Fibrinolysis. 2004 Jul;15(5):383-91
pubmed: 15205586
Lancet. 2009 Apr 4;373(9670):1175-82
pubmed: 19329177
Dis Markers. 2009;27(3):157-72
pubmed: 19893210
Circulation. 2009 Dec 1;120(22):2177-87
pubmed: 19917883
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
pubmed: 20027185
J Intern Med. 2010 Sep;268(3):296-308
pubmed: 20561148
Atherosclerosis. 2012 Feb;220(2):502-5
pubmed: 22119508
Atherosclerosis. 2012 May;222(1):8-14
pubmed: 22137664
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Int J Cardiol. 2013 Sep 10;167(6):2904-11
pubmed: 22909410
Am J Cardiol. 2012 Dec 15;110(12):1756-63
pubmed: 22981263
Clin Chem. 2013 Nov;59(11):1621-9
pubmed: 23842203
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
Eur J Heart Fail. 2014 Apr;16(4):377-83
pubmed: 24464777
Kidney Int. 2015 Jan;87(1):210-6
pubmed: 24897037
PLoS One. 2014 Jun 09;9(6):e98923
pubmed: 24911522
Atherosclerosis. 2014 Nov;237(1):60-6
pubmed: 25222341
J Am Heart Assoc. 2014 Oct 23;3(5):e001118
pubmed: 25341887
Int J Cardiol. 2015 Apr 1;184:631-6
pubmed: 25771228
Can J Cardiol. 2015 Oct;31(10):1223-4
pubmed: 26429353
N Engl J Med. 2015 Nov 12;373(20):1916-25
pubmed: 26539835
Nat Rev Nephrol. 2016 Jan;12(1):3
pubmed: 26592192
Kidney Int Rep. 2017 Mar;2(2):239-247
pubmed: 28367534
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1265-1273
pubmed: 28495863
Nat Med. 2017 Aug;23(8):945-953
pubmed: 28650456
Pflugers Arch. 2017 Aug;469(7-8):1017-1020
pubmed: 28689240
JAMA Pediatr. 2017 Nov 6;171(11):e172914
pubmed: 28873129
Kidney Int Rep. 2017 Feb 09;2(3):425-432
pubmed: 29142970